Equities

Sanofi India Ltd

SANOFI:NSI

Sanofi India Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)7,177.55
  • Today's Change-6.45 / -0.09%
  • Shares traded16.14k
  • 1 Year change+60.68%
  • Beta0.6086
Data delayed at least 15 minutes, as of Sep 19 2024 11:24 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in INRIncome statement in INRView more

Year on year Sanofi India Ltd had little change in net income (from 6.21bn to 6.03bn). Revenues were also little changed (from 27.70bn to 28.51bn.)
Gross margin55.95%
Net profit margin18.04%
Operating margin25.61%
Return on assets30.08%
Return on equity61.02%
Return on investment57.55%
More ▼

Cash flow in INRView more

In 2023, cash reserves at Sanofi India Ltd fell by 6.10bn. However, the company earned 2.30bn from its operations for a Cash Flow Margin of 8.08%. In addition the company generated 375.00m cash from investing, though they paid out 8.78bn more in financing than they received.
Cash flow per share203.20
Price/Cash flow per share35.17
Book value per share297.26
Tangible book value per share296.56
More ▼

Balance sheet in INRView more

Sanofi India Ltd uses little debt in its capital structure as supported by a debt to capital ratio of 3.13%.
Current ratio1.37
Quick ratio0.8140
Total debt/total equity0.0323
Total debt/total capital0.0313
More ▼

Growth rates in INR

Year on year, both dividends per share and earnings per share excluding extraordinary items growth dropped -13.92% and -2.85%, respectively. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
Div yield(5 year avg)2.14%
Div growth rate (5 year)14.73%
Payout ratio (TTM)62.69%
EPS growth(5 years)9.64
EPS (TTM) vs
TTM 1 year ago
-25.27
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.